NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
EpicentRx, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Gilead Sciences
National Cancer Institute (NCI)
New Mexico Cancer Research Alliance
Merrimack Pharmaceuticals
New Mexico Cancer Research Alliance
University of Alabama at Birmingham